Red Light Treatment in Peripheral Artery Disease

Part of paid clinical trials in Milwaukee, Wisconsin.

Sponsor
University of Alabama at Birmingham
Study ID
NCT03203239
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Red Light (670 nm energy) — DEVICE
    Light Emitting Diode light source (670 nm wavelength with output up to 75mW/cm2) will be placed over the gastrocnemius muscle. The light will be on for 5 minutes.
  • Octafluoropropane — DRUG
    All subjects will undergo infusion of octafluoropropane to measure peripheral blood flow.

Study Details

Subjects with a known diagnosis of peripheral artery disease as measured by an abnormal ankle brachial index (\<.9 or \>1.1) will undergo a single 5 min exposure of 670 nm light, 1 cm above the gastrocnemius muscle. Blood flow will be measured by infusion of ultrasound contrast and subsequent acquisition of ultrasound images. 2 blood samples will be collected for measurement of nitric oxide metabolites.

Key Dates

Start date
Jan 17, 2018
Status verified
Apr 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Red Light treatment
    This is a single arm design. All subjects will be enrolled to have peripheral blood flow measured before, during, and after red light exposure.

Primary Outcome Measure

Changes in blood flow [ Time Frame: Baseline, 5 min of light, and up to 1 min after discontinuation of light ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Medical College of WisconsinMilwaukeeWisconsin53226
Nicole L Lohr, MD PhD
[email protected]
205-996-3504

Find similar trials in Milwaukee, WI

By condition
Peripheral artery disease
By specialty
CardiologyVascular medicine
By research site
Medical College of Wisconsin· Milwaukee, WI

Related Studies